What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich ...

Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve ...